Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity
G Iacobellis, AC Villasante Fricke - Journal of the Endocrine …, 2020 - academic.oup.com
Abstract Background and Aims Epicardial adipose tissue (EAT), the visceral fat depot of the
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
G Iacobellis, ACV Fricke - Journal of the Endocrine Society, 2020 - scholarship.miami.edu
Abstract Background and Aims Epicardial adipose tissue (EAT), the visceral fat depot of the
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
[PDF][PDF] Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
G Iacobellis, ACV Fricke - 2020 - scienceopen.com
Materials and Methods. We performed a 12-week, controlled, parallel study in 80 subjects
with T2DM and obesity. Patients received either semaglutide, up to 1 mg subcutaneous (sc) …
with T2DM and obesity. Patients received either semaglutide, up to 1 mg subcutaneous (sc) …
Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
G Iacobellis, ACV Fricke - Journal of the Endocrine Society, 2020 - search.ebscohost.com
Abstract Background and Aims Epicardial adipose tissue (EAT), the visceral fat depot of the
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
[PDF][PDF] Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
G Iacobellis, AC Villasante Fricke - Journal of the Endocrine …, 2020 - academic.oup.com
Abstract Background and Aims Epicardial adipose tissue (EAT), the visceral fat depot of the
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and …
Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
G Iacobellis, ACV Fricke - Journal of the Endocrine Society, 2020 - go.gale.com
Background and Aims. Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is
a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and dulaglutide …
a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and dulaglutide …
Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
G Iacobellis, VF AC - Journal of the Endocrine Society, 2020 - europepmc.org
Materials and methods We performed a 12-week, controlled, parallel study in 80 subjects
with T2DM and obesity. Patients received either semaglutide, up to 1 mg subcutaneous (sc) …
with T2DM and obesity. Patients received either semaglutide, up to 1 mg subcutaneous (sc) …
Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
G Iacobellis, ACV Fricke - Journal of the Endocrine …, 2020 - pubmed.ncbi.nlm.nih.gov
Background and aims Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a
modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and dulaglutide …
modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and dulaglutide …
[HTML][HTML] Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
G Iacobellis, ACV Fricke - Journal of the Endocrine Society, 2020 - ncbi.nlm.nih.gov
Materials and Methods We performed a 12-week, controlled, parallel study in 80 subjects
with T2DM and obesity. Patients received either semaglutide, up to 1 mg subcutaneous (sc) …
with T2DM and obesity. Patients received either semaglutide, up to 1 mg subcutaneous (sc) …